Market Newsdesk

BOSTON, Dec. 30, 2020 /PRNewswire/ — The following notice relates to the combined Annual Meeting of Shareholders of Eaton Vance High Income 2021 Target Term Trust and Eaton Vance National Municipal Opportunities Trust:

Notice That Annual Meeting Of Shareholders

Will Be A Telephonic Meeting

Due to the public health impact of the coronavirus pandemic (COVID-19), travel guidelines in Massachusetts and surrounding areas, and to support the health and well-being of our shareholders, NOTICE IS HEREBY GIVEN that the combined Annual Meeting of Shareholders of Eaton Vance Eaton Vance High Income 2021 Target Term Trust and Eaton Vance National Municipal Opportunities Trust (each, a “Fund” and together, the “Funds”) to be held on Thursday, January 14, 2021 at 11:30 a.m. Eastern Time (the “Meeting”) will be held in a telephonic format. Shareholders will not be able to attend the Meeting in person.

If you were a record holder of Fund shares as of November 12, 2020 (i.e., you held Fund shares in your own name directly with the Fund), you are entitled to notice of and to vote at the Meeting or any postponement or adjournment thereof. To participate in the Meeting, please email AST Fund Solutions, LLC (“AST”) at [email protected], provide your full name and address and include the relevant Fund name(s) in the subject line.  AST will then email you the conference call dial-in information and instructions for voting during the Meeting.

If you held Fund shares through an intermediary (such as a broker-dealer) as of November 12, 2020, in order to participate in and vote during the Meeting, you must first obtain a legal proxy from your intermediary reflecting the relevant Fund name(s), the number of Fund shares you held, as well as your name and email address.  You may forward an email from your intermediary containing the legal proxy or attach an image of the legal proxy, email it to AST at [email protected] and put “Legal Proxy” in the subject line. Requests for registration must be received by AST no later than 3:00 p.m. Eastern Time on January 13, 2021.  AST will then email you the conference call dial-in information and instructions for voting during the Meeting.

The Funds and each Fund’s Board of Trustees are closely monitoring the evolving COVID-19 situation and if circumstances change, the Funds will issue additional press release(s) updating shareholders regarding the Meeting. Whether or not you plan to participate in the Meeting, we urge you to vote and submit your proxy in advance of the Meeting by one of the methods described in the proxy materials and to vote for the Trustees nominated for election at the Meeting. The proxy statement is available online at https://funds.eatonvance.com/closed-end-fund-and-term-trust-documents.php. The proxy card included with the previously distributed proxy materials will not be updated to reflect the change to a telephonic meeting and may continue to be used to vote your shares in connection with the Meeting. Please contact AST at [email protected] with any questions regarding accessing the Meeting and an AST representative will contact you to answer your questions.

By Order of the Boards of Trustees,

/s/ Maureen A. Gemma

Maureen A. Gemma

Secretary

About Eaton Vance Corp.

The Fund’s investment adviser is Eaton Vance Management, a subsidiary of Eaton Vance Corp.  Eaton Vance Corp. (NYSE: EV) provides advanced investment strategies and wealth management solutions to forward-thinking investors around the world. Through principal investment affiliates Eaton Vance Management, Parametric, Atlanta Capital, Calvert and Hexavest, the Company offers a diversity of investment approaches, encompassing bottom-up and top-down fundamental active management, responsible investing, systematic investing and customized implementation of client-specified portfolio exposures. As of October 31, 2020, Eaton Vance had consolidated assets under management of $515.7 billion. For more information, visit eatonvance.com.

View original content:http://www.prnewswire.com/news-releases/certain-eaton-vance-closed-end-funds-announce-telephonic-annual-meeting-of-shareholders-on-january-14-2021-301199309.html

SOURCE Eaton Vance Management

STOCKHOLM, Dec. 30, 2020 /PRNewswire/ — Bactiguard has received an initial order for coating concentrate from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate license revenues in the fourth quarter 2020 of approximately SEK 9 million. 

In parallel with the marketing and sales of Bactiguard’s BIP Foley urinary catheters in the Chinese market, Well Lead has made progress in the development of its own portfolio of medical devices, with Bactiguard’s coating for infection prevention. Well Lead has now placed an initial order for Bactiguard coating concentrate that will be used in product development and for manufacturing of products, pending regulatory product approval.

“I am pleased that we are making progress in our collaboration with Well Lead, despite the ongoing pandemic. Preparations for local production have now entered a phase where Well Lead needs Bactiguard’s coating concentrate. This also means that we, over time, are developing the partnership to include more products for infection prevention,” says Cecilia Edström, CEO.

In June 2018, Bactiguard signed a combined distribution and license agreement with Well Lead, China’s leading manufacturer of consumable medical devices. Initially, Well Lead has the exclusive right to market and sell Bactiguard’s urinary catheters (BIP Foley) in China. At the same time, the process of obtaining regulatory product approval for locally produced central venous catheters and endotracheal tubes, with Bactiguard’s technology for infection prevention was initiated.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-12-30, at 13.00.

For further information, please contact:

Cecilia Edström, CEO, phone: +46 8 440 58 80
 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bactiguard-holding-ab–publ-/r/new-order-from-china,c3262973

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/bactiguard-new-order-from-china-301199306.html

SOURCE Bactiguard Holding AB (publ)

LOS ANGELES, Dec. 30, 2020 /PRNewswire/ — LiveXLive Media (Nasdaq: LIVX) (“LiveXLive”), a global platform for livestream and on-demand audio, video and podcast content in music, comedy and pop culture, and owner of PodcastOne, Slacker Radio and React Presents, announced today that Maria Garrido has been appointed to the Company’s Board of Directors.  The appointment brings the total number of board members to ten.

Ms. Garrido is a multilingual, multinational executive with 24 years of experience in both operational and strategic roles in consumer goods, media, communications, and entertainment.  She is currently Senior Vice President of Brand Marketing at Vivendi Group (OTCPK: VIVEF) as well as Chief Insights Officer for Havas Group, where she leads a team of more than 300 people in 40+ countries and is responsible for the global Meaningful Brands study. Maria joined Havas in 2014 after 18 years of multi-national experience in North America, Latin America and Europe holdings at various companies, most notably Colgate-Palmolive and Mondelez. She is a prolific global public speaker, having appeared on Bloomberg news, The Guardian’s Summit, Cartagena Inspira, Mumbrella Australia, South Tech Summit, World Retail Congress, APAC Hall Healthcare Conference, IBC and IAB Mexico. She is a member of the International Women’s Forum and Marketing World50 and has also been a Media Jury member for Cristal Media Festival, Dubai Lynx, Cannes International Festival of Creativity, and President Entertainment Jury Eurobest. Maria is fluent in French, Spanish and English.

Robert Ellin, LiveXLive Chairman and CEO, commented, “We are pleased to have Maria join the LiveXLive Board. Her experience and acumen in international marketing and branding will be a welcome addition. I speak for our entire board in welcoming Maria to LiveXLive”.

Maria Garrido commented, “I am thrilled to be joining the LiveXLive Board at such an exciting time for the Company and the entertainment business overall. LiveXLive is visionary in its approach to artists, superfans and brands and is tirelessly committed to delivering enhanced entertainment experiences. LiveXLive is also completely in sync with the increasing demands of audiences today and is already clearly laying the groundwork for tomorrow’s growth. I look forward to being a part of this exciting company. ”

LiveXLive has the first talent-centric platform focused on superfans and building long-term franchises in on-demand audio and video, podcasting, vodcasting, OTT linear channels, pay-per-view (“PPV”), and livestreaming. Its model includes multiple monetization paths including subscription, advertising, sponsorship, merchandise sales, licensing, and ticketing. LiveXLive recently raised revenue guidance for its 2021 fiscal year based on strength in its core businesses.

About LiveXLive Media, Inc.

Headquartered in Los Angeles, California, LiveXLive Media, Inc. (NASDAQ: LIVX) (the “Company”) (pronounced Live “by” Live) is a global platform for livestream and on-demand audio, video and podcast content in music, comedy, and pop culture. LiveXLive, which has streamed over 1800 artists since January 2020, has become a go-to partner for the world’s top artists and celebrity voices as well as music festivals and concerts, including Rock in Rio, EDC Las Vegas, and many others. In April 2020, LiveXLive produced its first 48-hour music festival called “Music Lives” with tremendous success as it earned over 50 million views and over 5 billion views for #musiclives on TikTok with over 100 performances. The Company’s library of global events, video-audio podcasts and original shows are also available on Amazon, Apple TV, Roku and Samsung TVs in addition to its own app, destination site and social channels. The Company’s wholly-owned subsidiary, PodcastOne, generates more than 2.1 billion downloads annually across more than 350 podcast episodes per week.  For more information, visit www.livexlive.com and follow us on Facebook, Instagram, TikTok, Twitter at @livexlive, and YouTube.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: the Company’s reliance on one key customer for a substantial percentage of its revenue; the Company’s ability to consummate any proposed financing or acquisition and the timing of the closing of such proposed transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of any proposed transaction will not occur; the Company’s ability to continue as a going concern; the Company’s ability to attract, maintain and increase the number of its users and paid subscribers; the Company identifying, acquiring, securing and developing content; the Company’s intent to repurchase shares of its common stock from time to time under the stock repurchase program and the timing, price, and quantity of repurchases, if any, under the program; the Company’s ability to maintain compliance with certain financial and other covenants; the Company successfully implementing its growth strategy, including relating to its technology platforms and applications; management’s relationships with industry stakeholders; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of the Company’s subsidiaries; and other risks, uncertainties and factors including, but not limited to, those described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 26, 2020, Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 16, 2020, and in the Company’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements, except as may be required by law. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Press Contact:
For LiveXLive: The Rose Group 
Lynda Dorf
[email protected]

LiveXLive IR Contact:
310.601.2500
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/livexlive-appoints-vivendi-executive-maria-garrido-to-its-board-of-directors-301199239.html

SOURCE LiveXLive Media, Inc.

LAVAL, QC, Dec. 30, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted an additional new indication for DEXAVEN (dexamethasone phosphate) solution for injection, 4 mg/ml, for the treatment of COVID-19 in adult and adolescent patients (12 years of age and older weighing at least 40 kg) who require oxygen therapy. DEXAVEN is a corticosteroid that reduces inflammation. 

“We’re pleased that Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products has approved DEXAVEN for the treatment of symptoms due to COVID-19, because now patients in Poland have another treatment option to fight this virus,” said Thomas J. Appio, president, Bausch + Lomb/International, Bausch Health. “Bausch Health continues to evaluate our health care products and medicines around the world to determine if they may offer valuable treatment options for COVID-19, and we will continue to do what we can to assist in the global efforts to end the pandemic.”

Dexamethasone-containing products in the United States are not approved as a treatment for COVID-19 by the U.S. Food and Drug Administration. Patients should only use these products in accordance with their approved label and the directions of their doctor.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-healths-dexaven-dexamethasone-phosphate-receives-new-indication-in-poland-to-treat-patients-with-sars-cov-2-covid-19-301199175.html

SOURCE Bausch Health Companies Inc.

LISHUI, China, Dec. 30, 2020 /PRNewswire/ — Farmmi, Inc. (“Farmmi” or the “Company”) (NASDAQ: FAMI), an agriculture products supplier in China, today announced it received the prestigious Ecological High-Quality Agricultural Product designation for its Lishui Shangeng branded black fungus and dried mushrooms.  The designation from the Lishui Municipal Government recognizes product excellence.  Lishui Shangeng is a regional public brand signifying high-quality agricultural products in Lishui and other cities in Zhejiang.

Ms. Yefang Zhang, Farmmi’s Chairwoman and CEO, commented, “We are encouraged to end 2020 on another positive note.  We expect the prestigious Ecological High-Quality Agricultural Product designation will help to further differentiate our products and convey the premium we place on quality across our entire operations.  Our focus on brand and quality excellence continues to resonate with customers, including leading import/export companies, and drive growth, as seen by our recent sales announcements.  We believe we are firmly on track for an even better 2021 as we benefit from multiple catalysts, with broader demand growth, a dietary shift to inclusion of healthier foods and an improving global economic environment.  Our targeted investments in processing automation, supply chain and logistics, give us a significant competitive advantage with the quality and scale necessary to serve the increased customer demand we are seeing.” 

Ms. Zhang continued, “When taken together, Farmmi’s powerful brand can serve to drive improved profitability and lead to an even more robust supply chain as we are able to attract a broader base of farmers that want to participate in our development of a high-quality agriculture base.  We expect this coordinated promotion of ecological development to also lead to longer-term poverty alleviation and rural revitalization.”

As one of the earliest members of the Lishui Shangeng, Farmmi’s products also boast the Lishui Shangeng brand certificate. The Company makes full use of the premium Lishui Shangeng farming regional brand.  Strict quality control is at the core brand competitiveness, with the tenet of direct supply from the base, inspection access, and whole-process traceability. 

About Farmmi, Inc.

Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products.  The Company’s Farmmi Liangpin Market serves as a trading platform for Chinese geographical indication agricultural products and is a large platform for consumers to access locally sourced agricultural products. For further information about the Company, please visit: http://ir.farmmi.com.cn/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including the potential impact of COVID-19 on our business within and outside of China.  These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

View original content:http://www.prnewswire.com/news-releases/farmmi-receives-prestigious-high-quality-product-designation-301199223.html

SOURCE Farmmi, Inc.

ST. LOUIS, Dec. 30, 2020 /PRNewswire/ — Centene Corporation (NYSE: CNC) today announced that it has completed its acquisition of PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and treating rare diseases.

“We are pleased to welcome the PANTHERx team to the Centene family,” said Michael F. Neidorff, Chairman, President and Chief Executive Officer for Centene. “PANTHERx is a leader in rare disease pharmacy and brings a unique capability to our comprehensive pharmacy portfolio. Together, we will ensure patients living with complex and rare diseases get the quality care they deserve.”

As previously announced, PANTHERx and its management team will continue to operate independently as part of Centene’s Envolve Pharmacy Solutions, a total drug management program that includes integrated Pharmacy Benefit Manager (PBM) services and specialty pharmacy solutions to millions of members throughout the United States.

###

About Centene Corporation
Centene Corporation, a Fortune 50 company, is a leading multi-national healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace, the TRICARE program, and individuals in correctional facilities. The Company also serves several international markets, and contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and the development of its people, systems and capabilities so that it can better serve its members, providers, local communities, and government partners.

Centene uses its investor relations website to publish important information about the company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene’s investor relations website, http://investors.centene.com/.

Forward-Looking Statements

All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “seek,” “target,” “goal,” “may,” “will,” “would,” “could,” “should,” “can,” “continue” and other similar words or expressions (and the negative thereof). Centene (the Company, our, or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of our recently completed acquisition (the WellCare Acquisition) of WellCare Health Plans, Inc. (WellCare), other recent and future acquisitions, investments and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including but not limited to: the impact of COVID-19 on global markets, economic conditions, the healthcare industry and our results of operations, which is unknown, and the response by governments and other third parties; uncertainty as to our expected financial performance during the period of integration of the WellCare Acquisition; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical utilization rates due to the impact of COVID-19; the possibility that the expected synergies and value creation from the WellCare Acquisition will not be realized, or will not be realized within the expected time period; the risk that unexpected costs will be incurred in connection with the integration of the WellCare Acquisition or that the integration of WellCare will be more difficult or time consuming than expected; unexpected costs, charges or expenses resulting from the WellCare Acquisition; the inability to retain key personnel; disruption from the integration of the WellCare Acquisition, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; the risk that we may not be able to effectively manage our expanded operations;  competition; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; increased healthcare costs; changes in economic, political or market conditions; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act (ACA) and the Health Care and Education Affordability Reconciliation Act, collectively referred to as the ACA and any regulations enacted thereunder that may result from changing political conditions or judicial actions, including the ultimate outcome in “Texas v. United States of America” regarding the constitutionality of the ACA; rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting our government businesses; our ability to adequately price products on the Health Insurance Marketplaces and other commercial and Medicare products; tax matters; disasters or major epidemics; the outcome of legal and regulatory proceedings; changes in expected contract start dates; provider, state, federal, foreign and other contract changes and timing of regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including but not limited to Medicaid, Medicare, TRICARE or other customers); the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; challenges to our contract awards; cyber-attacks or other privacy or data security incidents; the possibility that the expected synergies and value creation from acquired businesses, including businesses we may acquire in the future, will not be realized, or will not be realized within the expected time period; the exertion of management’s time and our resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions; disruption caused by significant completed and pending acquisitions, including, among others, the WellCare Acquisition, making it more difficult to maintain business and operational relationships; the risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions; changes in expected closing dates, estimated purchase price and accretion for acquisitions; the risk that acquired businesses will not be integrated successfully; restrictions and limitations in connection with our indebtedness; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; availability of debt and equity financing, on terms that are favorable to us; inflation; foreign currency fluctuations and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission. This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition and results of operations, in our filings with the Securities and Exchange Commission (SEC), including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs.

View original content:http://www.prnewswire.com/news-releases/centene-completes-acquisition-of-pantherx-rare-pharmacy-pantherx-301199187.html

SOURCE Centene Corporation

BISMARCK, N.D., Dec. 30, 2020 /PRNewswire/ — Coulee Bank and BNCCORP, INC. (OTCQX Markets: BNCC) announced today that they have signed a definitive agreement for Coulee Bank to acquire certain loans and deposits of the Golden Valley, Minnesota, branch of BNC National Bank, a wholly owned subsidiary of BNCC. Coulee Bank will service the loans and deposits out of its existing St. Paul, Minnesota, office.

“Golden Valley offers a great opportunity to expand Coulee Bank’s customer base and to meet the evolving financial needs of our customers today and future customers of tomorrow. This will be Coulee Bank’s second banking acquisition in Minnesota and first since 2010 when it acquired $54 million in assets and one banking location in Minnesota,” said Dirk R. Gasterland, Chief Executive Officer of Coulee Bank.

BNCC Chairman Michael Vekich said, “This transaction and the subsequent closure of our Golden Valley branch, will permit our talented and dedicated leadership group and employee base to concentrate on providing the best service, products and solutions to our customers and communities in our core geographic markets in North Dakota and Arizona. The deal is a result of the Board’s strategic planning process and focus on improved execution, business, and financial performance, advancing strategic priorities, and maintaining the organization’s safe and sound practices in a volatile economic environment while driving sustainable shareholder value.”

The transaction is expected to involve approximately $16.5 million of deposits and $17.2 million of loans based on BNCC’s September 30, 2020, balance sheet. 

It is expected to be completed in the second quarter of 2021, subject to customary closing conditions, including regulatory approval. Terms of the definitive agreement were not disclosed.

ABOUT COULEE BANK
Coulee Bank is a privately owned bank with seven banking locations located in Minnesota and Wisconsin. As of September 30, 2020, Coulee Bank had assets of $434.8 million, deposits of $333.7 million, loans of $351 million and 80 employees.

ABOUT BNCCORP, INC.
BNCCORP, INC., headquartered in Bismarck, N.D., is a registered bank holding company dedicated to providing banking and wealth management services to businesses and consumers in its local markets. The Company operates community banking and wealth management businesses in North Dakota, Arizona, and Minnesota from 13 locations. BNC also conducts mortgage banking from 11 locations in Illinois, Kansas, Missouri, Michigan, Arizona, and North Dakota.

BNCC’S CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION.
This press release contains forward-looking statements regarding our expectations with respect to the planned acquisition by Coulee Bank of certain loans and deposits from BNC National Bank’s Golden Valley branch and the subsequent closing of that branch.

Forward-looking statements are necessarily subject to numerous assumptions, risks, and uncertainties, which change over time. Future events or circumstances may change our outlook and may also affect the nature of the assumptions, risk, and uncertainty to which our forward-looking statements are subject. The forward-looking statements in this press release speak only as of the date of this press release, and we assume no duty, and do not undertake, to update them. Actual results or future events could differ, possibly materially, from those that we anticipated in these forward-looking statements. As a result, we caution against placing undue reliance on any forward-looking statements.

Forward-looking statements in this press release are subject to risks and uncertainties related both to the acquisition transaction itself and the closure of BNC National Bank’s Golden Valley Branch, including that completion of the transaction is dependent on the satisfaction of customary closing conditions and regulatory approval, and that the closure of Golden Valley branch is also subject to regulatory approval, none of which can be assured. The timing of completion of the transaction is dependent on various factors that cannot be predicted with precision at this time.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coulee-bank-announces-agreement-to-acquire-loans-and-deposits-from-bnc-national-banks-golden-valley-branch-301199216.html

SOURCE BNCCORP, INC.